Bibby, A., De Fonseka, D., Morley, A. J., Keenan, E., Addeo, A., Smith, S., ... Maskell, N. (2017). Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: A prospective, observational, single centre study. *BMC Palliative Care, 16*(1), [71]. https://doi.org/10.1186/s12904-017-0255-3, https://doi.org/10.1186/s12904-017-0255-3

Early version, also known as pre-print

Link to published version (if available):
10.1186/s12904-017-0255-3
10.1186/s12904-017-0255-3

Link to publication record in Explore Bristol Research
PDF-document

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
EXPLORING THE CHARACTERISTICS OF PATIENTS WITH MESOTHELIOMA WHO CHOSE ACTIVE SYMPTOM CONTROL OVER CHEMOTHERAPY AS FIRST-LINE TREATMENT: A PROSPECTIVE, OBSERVATIONAL, SINGLE CENTRE STUDY

AUTHORS

Anna C Bibby¹,², Duneesha De Fonseka¹,², Anna J Morley², Emma Keenan¹, Alfredo Addeo³, Sarah Smith², Anthony J Edey⁴ & Nick A Maskell¹,²

AFFILIATIONS

1. Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, 2nd Floor L&R Building, Southmead Hospital, Bristol BS10 5NB
2. Department of Respiratory Medicine, North Bristol NHS Trust, Southmead Hospital, Bristol, BS10 5NB
3. Bristol Cancer Institute, Bristol Haematology & Oncology Centre, Horfield Rd, Bristol BS2 8ED
4. Department of Radiology, North Bristol NHS Trust, Southmead Hospital, Bristol, BS10 5NB

CORRESPONDING AUTHOR

Anna C Bibby
Address: Academic Respiratory Unit, University of Bristol, 2nd Floor L&R Building, Southmead Hospital, Bristol BS10 5NB
Email: Anna.Bibby@bristol.ac.uk
Tel: 01174148049
WORD COUNT, ABSTRACT – 258
WORD COUNT, BODY TEXT – 2671
NO OF TABLES/FIGURES – 2
NO OF REFERENCES – 17

ABBREVIATIONS
ASC – Active symptom control
CI – Confidence intervals
IQR – Interquartile range
MDT – Multidisciplinary team meeting
MPM – Malignant pleural mesothelioma
PS – Performance status
SD – Standard deviation
STRUCTURED ABSTRACT

Background: Mesothelioma is an aggressive thoracic tumour with a poor prognosis. The only treatment that extends survival is chemotherapy. However, in the UK, up to 50% of patients who are suitable for chemotherapy choose not to receive it, opting for active symptom control instead.

Aim: The aim of this study was to describe the characteristics of patients who chose active symptom control over chemotherapy and explore their reasons for doing so.

Design: A prospective, single-centre observational study.

Methods: 200 consecutive patients with mesothelioma from one UK centre were included. Eligibility for chemotherapy and choice of first-line treatment were recorded prospectively. Patient characteristics and outcomes were compared using descriptive statistics, regression analysis and survival analysis. Reasons for choosing active symptom control over chemotherapy were extracted, retrospectively.

Results: People who chose active symptom control were older, more likely to be female and had worse performance statuses than patients who received front-line chemotherapy. Concern over side effects, the modest survival benefit and previous adverse experiences with chemotherapy were reported as reasons for the decision.

Median survival was 13.9 months in the chemotherapy group compared with 6.7 months in the active symptom control group.
Conclusions: This is the first study to describe the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy, in the front-line setting. Important differences were seen between this group and patients who received chemotherapy, although confounding is likely to have affected some outcomes.

Future research could use qualitative methods to explore patients’ reasons for choosing active symptom control, and to further elucidate the decision-making process.

KEY WORDS
Mesothelioma
Active symptom control
Chemotherapy
Treatment decisions
Best supportive care
INTRODUCTION

Malignant pleural mesothelioma (MPM) is a universally fatal thoracic tumour with limited therapeutic options.\[1-4\] Chemotherapy is the current standard of care for first-line treatment, although the survival benefits are modest \[5-7\]. In a large randomised controlled trial and subsequent report from an expanded access program, the combination of cisplatin and pemetrexed demonstrated improvements in median survival of up to 4 months, compared with cisplatin alone.\[5, 6\] More recently the phase III MAPS trial showed that the addition of bevacizumab to this regimen extended survival by another 2.7 months, although this agent may not be suitable for everyone, and is not universally available.\[7\]

Multiple clinical trials are currently underway investigating novel agents, and it is anticipated that the future of MPM management will include a greater choice of treatment options than is currently available.

Aside from clinical trials, the current alternative to chemotherapy as first-line treatment for MPM is active symptom control (ASC). According to the 2007 British Thoracic Society Statement on Mesothelioma, ASC should include regular specialist follow-up and appropriate symptomatic treatment, such as analgesia, palliative radiotherapy and steroids as required.\[1\] In a randomised trial comparing mitomycin, vinblastine and cisplatin (MVP) or viorelbine chemotherapy with ASC, patients who received ASC alone had similar quality of life to patients who received chemotherapy.\[8\] That same trial, which is the only randomised study to have compared chemotherapy to active symptom control, also demonstrated no survival difference between the two groups.\[8\] However, the trial was undertaken in the pre-pemetrexed era and consequently these results cannot be extrapolated to modern chemotherapy regimens. Whilst the true effect of pemetrexed/cisplatin
chemotherapy versus no treatment is currently unknown, it is highly likely to exceed the 6 months survival benefit conferred by adding pemetrexed and bevacizumab to cisplatin.[5, 7]

Patients are considered eligible for first-line chemotherapy if they have a WHO performance status (PS) of 0 or 1 and no significant comorbidities.[2, 9, 10] Additionally, some patients who have a PS of 2 may be suitable to receive chemotherapy, based on individual assessment of their physical health.[9] In our centre, patients with MPM are discussed at a regional mesothelioma multidisciplinary team meeting (MDT), where the diagnosis is confirmed and eligibility for chemotherapy determined.[11] Eligible patients are offered first-line chemotherapy at their subsequent clinic appointment with their treating respiratory physician and given the chance to discuss the benefits and disadvantages of the planned treatment regimen with that clinician. Participants who wish to receive chemotherapy, or who wish to consult with an oncologist to discuss the matter further, are referred to an oncologist. Patients who state at the outset that they do not wish to receive chemotherapy are not referred to an oncologist.

A proportion of patients who are offered first-line chemotherapy make an informed decision to receive ASC instead. Epidemiological data collected in Leeds, UK between 2001 and 2005 reported that 28 out of 54 eligible patients (52%) declined chemotherapy.[12] More recently, the UK National Lung Cancer Audit revealed that chemotherapy uptake in MPM patients with PS 0-1 varied from 46% to 71% across UK centres.[2] Given that the majority of these patients would have
been eligible to receive front-line chemotherapy, it is likely that a proportion of
them made an active decision to receive ASC instead.

Epidemiological data from other countries is difficult to interpret, as performance
status and eligibility for chemotherapy is often omitted. However, Kao et al
proposed an optimal chemotherapy utilization rate of 65\% based on predictions of
eligibility.\cite{13} Chemotherapy usage rates of 36\% in the Netherlands between
2005 and 2006, and 54\% in Australia between 2007 and 2009 are both lower than
this proposed benchmark, again suggesting that a proportion of patients chose not
to receive chemotherapy despite being eligible.\cite{14, 15}

The aim of this study was to explore the characteristics of patients who chose to
receive ASC rather than first-line chemotherapy, and to determine what factors
were associated with this decision. This information is important, as a treatment
will only be effective if patients are willing to take it. Similarly, a new treatment
may demonstrate encouraging results in clinical trials, but its effectiveness will be
reduced if, in real-life, patients chose not to receive it. This is likely to become
increasingly pertinent as new treatments emerge for mesothelioma and become
adopted into usual clinical care.

Acknowledging there is a cohort of patients who decline first-line chemotherapy,
recognising their characteristics, and exploring their reasons for making this
choice may help improve treatment uptake in the future. Additionally, this
information will afford clinicians and allied health professionals a greater
understanding of their patients, and will lead to better communication, particularly
in discussions related to treatment decisions and chemotherapy.
METHODS

This was a prospective, observational, single-centre, UK-based study of consecutive patients with MPM enrolled in an ongoing prospective cohort study (Investigating Pleural Disease Study, Central Bristol REC approval 08/H0102/11 – see Appendix 1 for inclusion and exclusion criteria). All patients with a diagnosis of MPM were included, and all diagnoses of MPM were discussed and confirmed at the regional MPM MDT.

Baseline characteristics, symptoms and tumour variables (histological sub-type and IMIG stage[16]) were collected prospectively. Eligibility for first-line chemotherapy was determined at MDT and subsequently confirmed on an individual basis in oncology or respiratory clinics. Patients were considered eligible for front-line chemotherapy if they had a PS of 0 or 1 and no significant organ dysfunction (e.g. cardiac, renal or liver), or if they had a PS of 2 with good physical function and few co-morbidities.

The primary outcome was the proportion of patients who chose to receive ASC having been offered first-line chemotherapy. This decision was recorded prospectively on the study database. Patients’ reasons for choosing ASC were obtained from retrospective interrogation of medical records and clinic letters. Potential reasons for choosing ASC were not defined a priori, as this was considered a hypothesis generating exercise.

The characteristics of patients who were offered first-line chemotherapy and chose ASC were compared with patients who accepted first-line chemotherapy. Chi
squared test was used for categorical variables, with Fishers Exact test employed if any individual value was less than 10. Unpaired two-tailed T tests were used for normally-distributed continuous variables and Wilcoxon Rank Sum for non-parametric continuous data. Univariable and multivariable logistic regression was used to explore associations between baseline characteristics and choosing ASC.

The secondary outcome was survival, calculated from date of diagnosis to date of death, censored on 26/06/2017. Survival was calculated for all MPM patients who were offered chemotherapy. Survival in patients who were offered first-line chemotherapy and chose ASC was compared with patients who accepted first-line chemotherapy. Kaplan Meier curves were drawn to visually compare survival between these two groups. Cox Proportional Hazards model was used, with adjustment for age, sex, laterality, PS, histology, stage and symptoms.

Apart from patients’ reasons for choosing ASC, all data were collected prospectively on the study database. Relevant data was extracted from the database by one of the authors (ACB) using a standardised data collection form (shown in Appendix 2). Patients’ reasons for choosing ASC were obtained retrospectively from patient records.

RESULTS

200 patients with MPM enrolled in the study between 1/3/08 and 8/6/16, of whom 150/200 (75%) were considered eligible for first-line chemotherapy at initial assessment. 10/150 (6.7%) subsequently became ineligible due to a rapid deterioration in PS between baseline assessment and discussion about
chemotherapy. Data were missing on 1 patient who moved out of the area, and was lost to follow up. This person’s data are not included in the analysis.

**Primary outcome**

Of 139 patients offered first-line chemotherapy, 93 (66.9%) accepted and 46 (33.1%) chose ASC. The characteristics of these patients are shown in Table 1.

The group that chose ASC were older than those who accepted chemotherapy (mean age 74.4 vs 68.4, p<0.001) and consisted of a higher proportion of females (23.9% vs 10.8%, p=0.041). Additionally the group that chose ASC had worse PS than the group that chose chemotherapy, with fewer PS 0 patients (17.4% vs 43.0%) and more PS 1 (69.6% vs 51.6%) and PS 2 patients (13.0% vs 5.4%, p=0.005). There was no difference in laterality, histology, stage, symptoms or blood tests between the groups. Of the patients who chose ASC, all 46 received their diagnosis from a respiratory physician, with whom they were involved in a discussion about first-line chemotherapy. 22/46 (47.8%) stated their decision to pursue ASC to the respiratory physician and consequently were not seen by an oncologist. 24/46 (52.2%) consulted with both respiratory physician and oncologist before deciding to pursue ASC.

In multivariable logistic regression analysis, the factors independently associated with choosing ASC were age (p<0.001) and PS (p=0.024).
Table 1 - Characteristics of patients who were offered first-line chemotherapy, who chose ASC or chemotherapy

|                         | Received chemotherapy | Chose ASC | p      |
|-------------------------|-----------------------|-----------|--------|
| **Total (n=139)**       |                       |           |        |
| **Sex, n (%)**          |                       |           |        |
| Male                    | 83 (89.2)             | 35 (76.1) | 0.041  |
| Female                  | 10 (10.8)             | 11 (23.9) |        |
| **Laterality, n (%)**   |                       |           |        |
| Right                   | 54 (58.1)             | 27 (58.7) | 0.943  |
| Left                    | 39 (41.9)             | 19 (41.3) |        |
| **Age, mean (SD)**      | 68.4 (6.36)           | 74.4 (7.35) | <0.001 |
| **Performance status, n (%)** |                 |           |        |
| 0                       | 40 (43.0)             | 8 (17.4)  |        |
| 1                       | 48 (51.6)             | 32 (69.6) |        |
| 2                       | 5 (5.4)               | 6 (13.0)  |        |
| **Histology, n (%)**    |                       |           |        |
| Epithelioid             | 63 (67.7)             | 36 (78.3) |        |
| Sarcomatoid             | 15 (16.1)             | 6 (13.0)  |        |
| Biphasic                | 9 (9.7)               | 1 (2.2)   |        |
| Desmoplastic            | 2 (2.2)               | 1 (2.2)   |        |
| Not specified           | 4 (4.3)               | 2 (4.4)   |        |
| **IMIG tumour stage, n (%)** |                   |           |        |
| IA                      | 28 (30.1)             | 15 (32.6) | 0.540  |
| IB                      | 6 (6.5)               | 0         |        |
| II                      | 7 (7.5)               | 3 (6.5)   |        |
| IIIA                    | 30 (32.2)             | 13 (28.2) |        |
| IIIB                    | 10 (10.75)            | 7 (15.2)  |        |
| IV                      | 12 (12.9)             | 8 (17.4)  |        |
| Not documented          |                       |           | 0.543  |
| **Symptoms, n (%)**     |                       |           |        |
| Chest pain              | 38 (40.9)             | 22 (47.8) | 0.435  |
| Breathlessness          | 75 (80.7)             | 39 (84.8) | 0.550  |
| Cough                   | 42 (45.1)             | 18 (39.1) | 0.499  |
| Systemic symptoms       | 37 (39.8)             | 22 (47.8) | 0.367  |
| (sweats, weight loss, fatigue) |                     |           |        |
| **Blood tests, median (IQR)** |     |           |        |
| Haemoglobin, g/dL       | 138 (126-150)         | 132.5 (121-149) | 0.263  |
| Neutrophils, x10^9/L    | 5.73 (4.80-7.00)      | 5.84 (4.28-7.00) | 0.729  |
| Lymphocytes, x10^9/L    | 1.6 (1.15-2.15)       | 1.32 (1.00-1.94) | 0.076  |
| Albumin, g/L            | 35 (31-38)            | 34 (30-38) | 0.456  |
| Neutrophil Lymphocyte Ratio (NLR) | 4.00 (2.73-5.38) | 4.18 (3.09-6.38) | 0.255  |

ASC = active symptom control  SD = standard deviation, IQR = interquartile range
Patients’ reasons for choosing ASC over first-line chemotherapy were documented in 15/46 (32.6%) cases. Reasons included concern that the benefits of chemotherapy did not justify the risk of side effects (5/15), a desire to prioritise quality of life in the context of no current symptoms (4/15), needle or hospital-phobia (3/15) and pursuit of alternative, experimental treatment in another country (1/15). Two (2/15) patients reported previous negative experiences with chemotherapy as their reason for choosing ASC. One of these patients had received chemotherapy for previous ovarian cancer, whilst the other had cared for his brother whilst he received chemotherapy for lung cancer.

Secondary outcome – survival

Median survival for all 139 MPM patients who were eligible for chemotherapy was 13.1 months (interquartile range (IQR) 7.3 – 20.0 months). Median survival in patients who received first-line chemotherapy was 14.5 months, compared with 9.8 months in patients who chose ASC having been offered first-line chemotherapy (hazard ratio (HR) 0.59, 95% CI 0.40 – 0.87, p=0.007). Kaplan Meier survival curves are shown in Figure 1.

In multivariable cox regression analysis, factors independently associated with poor survival were PS of 2 (HR 2.45, 95% CI 1.09-5.50, p=0.03), non-epithelioid histology (HR 1.79, 95% CI 1.16-2.76, p=0.009), stage (HR 1.21, 95% CI 1.09-1.34, p<0.001), breathlessness at diagnosis (HR 1.90, 95% CI 1.02-3.50, p=0.042) and not receiving chemotherapy (HR 1.86, 95% CI 1.15-2.99, p=0.011).
Figure 1 - Kaplan Meier curves comparing survival in patients who chose ASC with those chose chemotherapy

DISCUSSION

This is the first study to report the characteristics of patients with MPM who were offered first-line chemotherapy but declined it in favour of ASC. In this prospective study of 139 patients, significant differences were observed between people who chose ASC and those who chose chemotherapy. This is an important finding in understanding attitudes to treatment in MPM, and potential factors affecting treatment decisions. Further research is needed to explore patient's motivations for choosing ASC in greater depth, and the use of qualitative research methods could provide rich and informative data on this subject.

A strength of this study is the lack of missing data. Apart from one patient who moved out of the region, treatment choice and survival data was available for all patients. Data on tumour stage and histology was not recorded for a proportion of
patients; but this is a phenomenon that has been observed nationally.[2] Overall, however, data completeness was high for this cohort, and this is likely to be a result of prospective data collection and rigorous database management.

Patients’ reasons for choosing ASC were collected retrospectively, and consequently were only available for one third of participants. Missing data is a recognised limitation of retrospective data collection, and may have introduced bias in this domain. It is acknowledged that the reasons for declining chemotherapy reported in this paper may not be representative of the whole group and that alternate reasons, not reported here, may also exist. Given the semi-qualitative nature of this outcome measure, results should be seen as hypothesis-generating, rather than conclusive. However, future studies would benefit from prospective collection of this information.

This study describes patients seen at a single UK centre and the results may not be generalizable. However, many of the findings from this study replicate other observational MPM studies. The male preponderance, the higher incidence of right-sided disease and the predominance of epithelioid sub-type are consistently reported, and are reproduced here.[2, 3, 9] Additionally the proportion of patients who were eligible for first-line chemotherapy, and the percentage of those people who went on to receive it were consistent with national rates, suggesting practice at our centre is similar to other centres in the UK.[2, 9] Finally, median survival of all MPM patients was comparable to previously reported survival times for MPM.[2-4, 9] The similarities between our cohort and national data suggest that patients in this study are representative of MPM patients in general. However, it is not known whether the characteristics of patients who choose ASC are the same in
other centres. Further studies are needed to see whether similar results are observed elsewhere.

There was a difference in median survival of 7.2 months between patients who chose ASC and those who received first-line chemotherapy. Although no study has ever compared cisplatin and pemetrexed chemotherapy with ASC, it is likely that this survival difference represents more than just the biological effect of chemotherapy. Confounding due to the non-randomised, observational study design will have influenced survival, in that patients who chose ASC had worse prognostic features, such as increased age and poorer PS. Additionally, unmeasurable factors may have contributed. For example, patients who chose ASC may have been less likely to seek medical help for other (treatable) medical problems, which could have impacted on their overall survival.

Where reasons for choosing ASC were given, they were varied and included concerns about chemotherapy side-effects and appreciation of the limited benefit offered by current first-line chemotherapy agents. Causal relationships cannot be assumed on the basis of this observational study. However, it may be that patients who were older and frailer had greater concerns about chemotherapy toxicity and were consequently more likely to choose ASC. Qualitative interviews around patients’ reasons for choosing ASC would be valuable in exploring this possibility in greater detail. Qualitative methods could also describe other potential reasons for choosing ASC or declining chemotherapy, and could reveal important factors in the decision-making process.
Several of the reasons given by patients for declining chemotherapy in this study have been reported in other studies of older adults with cancer, including concern about side effects, the wish to prioritise quality of life, and previous negative treatment experiences.[17] Additional reasons for declining cancer treatment that have been reported in the literature include low mood and fear of becoming a burden on others/losing independence.[17] These factors were not reported in our cohort, but neither were they actively enquired about, due to retrospective data collection. Since none of the existing literature focuses specifically on people with mesothelioma, these are important areas that could be explored in future research in this patient group. Further factors affecting decision making around cancer treatments include financial considerations and transportation difficulties.[17] Whilst these issues may be less relevant in the UK where the NHS provides free universal healthcare, and hospital transportation is readily available, they may still be worth including in future prospective and qualitative research.

An important point to be considered in the interpretation of this study is the interaction between clinician and patient when discussing treatment options. It is possible that conversations regarding oncological treatments were more circumspect in older patients with poorer performance status, and that this influenced patient’s decisions. Clinician’s preferences, whether conscious or subconscious, implicit or explicit, could have affected the dynamic of the consultation and swayed patients towards ASC. An ethnographic, observational approach, or detailed conversation analysis, could be employed to investigate this possibility.

This study has highlighted the heterogeneity of patients with MPM, and identifies a specific sub-set of patients who choose not to have first-line chemotherapy.
Further research is warranted to determine whether these findings are replicated in other centres and, indeed, other countries. Exploring patients’ attitudes to chemotherapy, and understanding the factors affecting the decision-making process could be the first step towards increasing treatment uptake, and potentially improving survival for MPM in the future.

CONCLUSION

This is the first study to describe the characteristics of patients with mesothelioma who chose ASC over front-line chemotherapy. In this single-centre, UK-based study, participants who chose ASC were older, more likely to be female, and had worse performance status than those who accepted chemotherapy. Recognising these patients and understanding their motivations could improve communication and enhance the relationship between clinicians and patients.

ETHICAL APPROVAL

Investigating pleural disease, improving the patient pathway was granted a favourable opinion by Research Ethics Committee South-West – Central Bristol in June 2014, reference 08/H0102/11/AM06. All patients in the study provided written, informed consent for participation.

CONSENT FOR PUBLICATION

N/A

AVAILABILITY OF DATA
Data for this study includes potentially identifiable information and sensitive personal data and is therefore not available publically.

CONFLICTS OF INTERESTS
Nick A Maskell has received an unrestricted research grant from CareFusion (San Diego, California; USA) and has sat on the advisory board for CareFusion. NAM is Chairman of the British Thoracic Society Mesothelioma Guidelines Committee and is a member of the European Respiratory Society Mesothelioma Guideline Committee.

The remaining authors declare no conflicts of interest or funding received.

FUNDING
This work was supported by a Research Capability Funding Award granted to Dr Anna Bibby by North Bristol NHS Trust Research & Innovation Department in December 2015.

AUTHORS’ CONTRIBUTIONS
ACB conceived and designed the study, with support from NAM. All authors were involved in patient identification, data collection and database maintenance. ACB undertook the statistical analysis which was reviewed by DDF and NAM. ACB wrote the final paper, which was reviewed and approved by all the authors.

ACKNOWLEDGEMENTS
N/A
REFERENCES

1. British Thoracic Society Standards of Care C: BTS statement on malignant mesothelioma in the UK, 2007. Thorax 2007, 62 Suppl 2:ii1-ii19.

2. Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Peake MD: Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales. Lung Cancer 2015, 88(3):344-348.

3. Linton A, Pavlakis N, O’Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N: Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. British Journal of Cancer 2014, 111(9):1860-1869.

4. Robinson BM: Malignant pleural mesothelioma: an epidemiological perspective. Annals of Cardiothoracic Surgery 2012, 1(4):491-496.

5. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644.

6. Bloss J, Wozniak T, Janne P, Belani C, Keohan M, Ross H, Polikoff J, Mintzer D, Taylor L, Obasaju C: Survival update on a subset of peritoneal mesothelioma (PM) patients in an expanded access program (EAP) of pemetrexed (P) alone or combined with cisplatin in the treatment of malignant mesothelioma (MM). J Clin Oncol 2005, 23(16_suppl):7174-7174.

7. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V et al: Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2015.
8. Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CMB, Lowry E, Nicholson AG, O’Brien M, Peake M, Rudd R et al: Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008, 371(9625):1685-1694.

9. National Lung Cancer Audit Report 2014, mesothelioma. Report for the period 2008–2012

10. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982, 5(6):649-656.

11. Bibby AC, Williams K, Smith S, Bhatt N, Maskell NA: What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the UK. BMJ Open 2016, 6(9).

12. Chapman A, Mulrennan S, Ladd B, Muers MF: Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 2008, 63(5):435-439.

13. Kao SC-H, van Zandwijk N, Clarke S, Vardy J, Lumba S, Tognela A, Ng W: Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: An evidence-based benchmark for cancer care. Asia-Pacific Journal of Clinical Oncology 2015, 11(1):85-92.

14. Damhuis RAM, Schrotten C, Burgers JA: Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. European Respiratory Journal 2012, 40(1):185-189.

15. Kao SH, Clarke S, Vardy J, Corte P, Clarke C, Zandwijk N: Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. Internal medicine journal 2013, 43(4):402-410.
16. Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. *Chest* 1995, **108**(4):1122-1128.

17. Puts MT, Tapscott B, Fitch M, Howell D, Monette J, Wan-Chow-Wah D, Krzyzanowska M, Leighl NB, Springall E, Alibhai SM: A systematic review of factors influencing older adults’ decision to accept or decline cancer treatment. *Cancer treatment reviews* 2015, **41**(2):197-215.
APPENDIX 1 – Inclusion and exclusion criteria for the Investigating Pleural Disease study

**Inclusion criteria:**

1/. Undiagnosed/malignant pleural effusion or pleural thickening requiring investigation.

and

2/. Pleural aspiration or CT scan form part of the clinical plan.

Or

3/. Patients with a confirmed diagnosis of mesothelioma

**Exclusion criteria:**

1/. Inability to give informed written consent

2/. Pregnancy or lactation

3/. Declines follow up to diagnosis or 12 months.
### APPENDIX 2 – Data collection form

| Participant ID: |  |
|----------------|---|
| Gender: Male | Female |
| Age at diagnosis: | |
| Date of diagnosis: | |
| **Co-morbidities** | |
| Cardiac | Yes | No |
| Renal | Yes | No |
| Other | Yes | No |
| **What other?** | |
| **Symptoms at presentation** | |
| Chest pain | Yes | No |
| Breathlessness | Yes | No |
| Cough | Yes | No |
| Fatigue | Yes | No |
| Sweats | Yes | No |
| Weight loss | Yes | No |
| **Performance status** | 0 | 1 | 2 | 3 | 4 |
| **Referred by:** | GP | Resp team | Ward/inpatient | MAU | Other hospital |
| **Biopsy method** | VATS | LAT | CT guided | US guided | Unknown |
| **Histological sub-type:** | Epithelioid | Sarcomatoid | Biphasic | Desmoplastic | NOS |
| **Laterality** | Left | Right | Not stated |
| **TNM stage** | |
| **IMIG stage** | Ia | Ib | II | III | IV | Not stated |
| **Bloods at diagnosis** | |
| Haemoglobin | |
| Neutrophils | |
| Lymphocytes | |
| Neut/lymph ratio | |
| Albumin | |
| **Eligible for chemo** | Yes | No |
| **Discussed with?** | Pulmonologist | Oncologist |
| **Treatment decision** | Chemo | ASC |
| **Reason for choosing ASC** | |
| **Outcome** | Died | Censored |
| **Survival (months)** | |